ANAPTYSBIO, INC. Shareholders' Equity
ANAPTYSBIO, INC. (ANAB) had Shareholders' Equity of $10.59 million as of 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-09-21
- 2026-06-30: Stockholders' Equity Attributable to Parent $10.59M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $12.75M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $37.21M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$29.42M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $10.59M 10-KT · filed 2026-09-21 |
| 2026-03-31 | $12.75M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $37.21M 10-KT · filed 2026-09-21 |
| 2025-09-30 | -$29.42M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$44.73M 10-Q · filed 2025-11-04 |
| 2025-03-31 | $34.02M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $70.87M 10-KT · filed 2026-09-21 |
| 2024-09-30 | $84.37M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $9.88M 10-Q · filed 2025-11-04 |
| 2024-03-31 | $47.78M 10-Q · filed 2025-11-04 |
| 2023-12-31 | $88.10M 10-KT · filed 2026-09-21 |
| 2023-09-30 | $120.38M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $148.45M 10-Q · filed 2024-11-05 |
| 2023-03-31 | $191.09M 10-Q · filed 2024-11-05 |
| 2022-12-31 | $262.10M 10-K · filed 2026-03-03 |
| 2022-09-30 | $277.62M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $304.31M 10-Q · filed 2023-11-02 |
| 2022-03-31 | $330.75M 10-Q · filed 2023-11-02 |
| 2021-12-31 | $356.43M 10-K · filed 2025-02-27 |
| 2021-09-30 | $383.61M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $385.73M 10-Q · filed 2022-11-08 |
| 2021-03-31 | $381.94M 10-Q · filed 2022-11-08 |
| 2020-12-31 | $396.73M 10-K · filed 2024-03-11 |
| 2020-09-30 | $360.24M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $381.44M 10-Q · filed 2021-11-04 |
| 2020-03-31 | $400.56M 10-Q · filed 2021-11-04 |
| 2019-12-31 | $405.01M 10-K · filed 2023-03-01 |
| 2019-09-30 | $420.89M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $448.42M 10-Q · filed 2020-11-04 |
| 2019-03-31 | $468.15M 10-Q · filed 2020-11-04 |
| 2018-12-31 | $486.37M 10-K · filed 2022-03-07 |
| 2018-09-30 | $499.68M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $284.98M 10-Q · filed 2019-11-08 |
| 2018-03-31 | $294.53M 10-Q · filed 2019-11-08 |
| 2017-12-31 | $307.58M 10-K · filed 2021-02-25 |
| 2017-09-30 | $101.36M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $109.17M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $110.11M 10-Q · filed 2017-05-12 |
| 2016-12-31 | -$38.25M 10-K · filed 2020-03-02 |
| 2015-12-31 | -$35.18M 10-K · filed 2019-02-28 |
| 2014-12-31 | -$30.84M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |